What happened?
The EORTC Breast Cancer Group (770+ members) summarises current research across early and metastatic disease, including the phase III EORTC‑2129 TREAT ctDNA trial (ctDNA screening: 1,129 entered; 46 randomised by Sept 2026), APPALACHES (373 randomised) and extensions of molecular screening programmes. Two 20‑year follow‑up papers on lymph node radiotherapy were published.
Why does it matter?
These activities aim to refine treatment choices, reduce unnecessary therapy and measure long-term effects of interventions. The 20‑year analyses show reduced breast cancer mortality with internal mammary/medial supraclavicular irradiation but no overall survival gain because of later non‑breast cancer deaths, highlighting late harms to monitor.
How to interpret the evidence
Findings come from international academic trials and long follow‑up; applicability to individual patients depends on local practice, patient selection and availability of tests or trials in EU/Malta. Some studies are ongoing and recruitment or national funding vary, so results and access may not be immediately applicable in every country.
What remains uncertain?
This summary does not imply new regulatory approvals or routine changes in care. Ongoing randomised trials and long‑term analyses inform potential future practice but external validation, local guideline review and assessment of late risks are required before changing standard treatment.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.
This summary was prepared with AI assistance and checked automatically against the linked primary source. It has not been individually reviewed by a clinician.